Antimicrobial resistance is a serious threat to public health, patient safety, and national security. IDSA is working on multiple fronts to strengthen the United States’ response to antimicrobial resistance including the efforts of the Interagency Task Force on Antimicrobial Resistance [chaired by the Centers for Disease Control and Prevention (CDC), National Institute of Allergy and Infectious Diseases (NIAID), and Food and Drug Administration (FDA)] formed in the late 1990’s as well as the Trans-Atlantic Task Force on Antimicrobial Resistance (TATFAR) formed by the U.S. and European Union in November 2009. We seek better overall leadership and coordination of US activities, strengthened funding, and enhanced surveillance, prevention and control, data collection, and research efforts. For this reason, IDSA enthusiastically endorses the Strategies to Address Antimicrobial Resistance (STAAR) Act, which, if enacted, would support the Interagency Task Force’s work and elevate the federal response overall. We also seek strengthened federal funding.
IDSA, Pew Mobilize Support for AMR Reporting
IDSA and Pew co-led a letter signed by over 40 organizations in support of proposed hospital reporting antibiotic use and resistance data to CDC.
COVID-19’s Impact on Antimicrobial Resistance and Healthcare-Associated Infections
New infographic outlines key data, including additional 24% of hospital-onset multidrug resistant infections than expected between March – September 2020.
IDSA and Sepsis Alliance Letter to Congress
IDSA and the Sepsis Alliance sent a letter to Congress calling attention to the intersection of antimicrobial resistance and sepsis and health equity in addition to the Pledge for Equity, Diversity, and Inclusion.
IDSA Cancer Fact Sheet
IDSA fact sheet on cancer, anti-microbial resistance challenges and the path forward.
FY2022 Pingree-Carter House AMR Funding Letter
Letter to House Labor, Health, and Human Services Appropriations Subcommittee led by Reps. Chellie Pingree (D-ME) and Buddy Carter (R-GA) and 61 House members in support of increased FY2022 funding for domestic and global antimicrobial resistance programs.
IDSA Cures 2.0 Comments
IDSA recommendations on bipartisan legislation addressing pandemic preparedness issues, including antimicrobial resistance, testing strategies and coverage, diversity in clinical trials, and the research workforce.
IDSA Outreach to New HHS Secretary
IDSA wrote to Secretary Becerra to highlight priorities, including COVID-19, AMR, ID workforce and investments in domestic and global public health and ID research.
IDSA Leads Letter to House on AMR Funding
The partner organizations of the Stakeholder Forum on Antimicrobial Resistance (S-FAR), convened by IDSA, sent a letter to House Appropriations making the case for full funding for federal antimicrobial resistance programs in FY2022.
IDSA Leads Letter to Senate on AMR Funding
The partner organizations of the Stakeholder Forum on Antimicrobial Resistance (S-FAR), convened by IDSA, sent a letter to Senate Appropriations making the case for full funding for antimicrobial resistance programs.
IDSA Comments on Ranking of Antimicrobials
IDSA letter providing input on FDA proposed approach for ranking antimicrobial drugs according to their importance in human medicine.
Sign-on Letter in Support of PASTEUR ACT
IDSA and over 40 other health organizations come together in support of a bill that supports Antibiotic Stewardship and R&D
IDSA Presents at FDA Meeting Ranking on Antimicrobials
IDSA offers feedback on draft FDA approach tp ranking antimicrobial drugs according to their importance in human medicine.
IDSA Letter to Senate on FY2021 Funding
IDSA and other health organizations thank the Senate for current FY2021 funding while highlighting areas and organizations for increased funding.
IDSA Letter to House on FY2021 Funding
IDSA and other health organizations thank the House for current FY2021 funding while highlighting areas and organizations for increased funding.
IDSA Supports FORWARD Act (PDF)
IDSA offers strong support for H.R. 2858, the Finding Orphan-Disease Remedies with Antifungal Research and Development (FORWARD) Act, which addresses several important issues related to neglected fungal diseases.
IDSA Testimony RE Antimicrobial Resistance and National Security (PDF)
IDSA testimony on the implications of antimicrobial resistance for national security, submitted to the US House of Representatives Committee on Oversight and Reform Subcommittee on National Security.
IDSA Comments to HHS Re Antimicrobial Resistance and the National Biodefense Strategy (PDF)
IDSA supports the National Biodefense Strategy, particulary the goals and objectives related to AMR domestically and internationally, and shared policy recommendations to combat AMR.
S-FAR Sign On Letter in Support of AMR Goals and Objectives in National Biodefense Strategy (PDF)
IDSA and 47 other organizations representing health provider and scientific societies, patient groups, public health associations, hospitals and academic institutions, policy expert groups, pharmaceutical and diagnostic companies, and individual centers and programs, applaud the inclusion of antimicrobial resistance in the National Biodefense Strategy and support its AMR goals and objectives.
IDSA Leads Sign On Letter to HHS Secretary on AMR (PDF)
IDSA led a group of over forty organizations representing health care providers, patients, public health, and industry to thank HHS Secretary Tom Price for his upcoming participation in the World Health Assembly, and to continue domestic and international work to advance a robust response to antimicrobial resistance (AMR) that reflects the US commitment to infection prevention, antimicrobial stewardship, surveillance, and innovation.
IDSA Leads Health Groups in Letter to New Administration Urging Continuation of AMR Efforts (PDF)
IDSA coordinated a letter, joined by 47 other health groups, to President-elect Trump urging that federal efforts to combat antimicrobial resistance be maintained in the years ahead.
IDSA Letter of Introduction to ASPR Robert Kadlec (PDF)
IDSA letter of introduction to new Assistant Secretary for Preparedness and Response (ASPR) Dr. Robert Kadlec outlining IDSA priorities.
IDSA Introduction to FDA Commissioner Gottlieb (PDF)
IDSA wrote an introductory letter to recently confirmed US Food and Drug Administration (FDA) Commissioner Dr. Scott Gottlieb offering its support and highlighting the need for new antibiotic research and development and infectious disease diagnostics.
IDSA Highlights Pressing ID Policy Issues for New HHS Secretary (PDF)
IDSA outlines a number of pressing ID policy priorities for new HHS Secretary Dr. Tom Price, including antimicrobial resistance, domestic and global public health programs, infrastructure, and preparedness, biomedical research and innovation, and ID physician workforce issues.
IDSA Outlines ID Policy Issues for Trump Transition Team (PDF)
IDSA outlines important ID policy issues for Vice President-elect Mike Pence, head of the Trump Transition Team.
IDSA Comments to PACCARB (PDF)
IDSA presented comments at a public meeting of the Presidential Advisory Council on Antibiotic-Resistant Bacteria (PACCARB). IDSA applauded the PACCARB for its work so far on the five goals of the National Action Plan for Combating Antibiotic Resistant Bacteria, and highlighted specific recommendations to advance each of the goals in the National Action Plan.
IDSA Comments to PACCARB on Antibiotic Resistance Data Collection (PDF)
IDSA comments to the Presidential Advisory Council on Combating Antibiotic-Resistant Bacteria on challenges faced in gathering and sharing antibiotic resistance data.
IDSA Applauds FDA and NIH for Advancing Federal Dialogue on Antibiotic Resistance (PDF)
In a letter to U.S. Food and Drug Administration (FDA) commissioner Margaret Hamburg and National Institutes of Health (NIH) director Francis Collins, IDSA thanks the respective agencies for holding a productive and thought provoking public workshop on antimicrobial product development and enthusiastically welcomes NIH’s announcement of a forthcoming public-private partnership (PPP) to address antibiotic development and related effort to establish a master clinical trials protocol. IDSA has long advocated for a high-level PPP with representation from the federal government, academia, industry, physicians and other key stakeholders, to promote innovation and improvement in the discovery, development, and evaluation of new antibiotics and diagnostics.
IDSA Calls on President Obama to Fulfill SOTU Pledge on Antibiotic Resistance (PDF)
IDSA applauds President Obama for highlighting the need to address resistance during his State of the Union address and urges him to take specific actions, including incentivizing development of new antibiotics and diagnostics, strengthening stewardship, improving surveillance, and investing in research.